Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cartron, G.
Right arrow Articles by Watier, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cartron, G.
Right arrow Articles by Watier, H.
Related Collections
Right arrow Neoplasia
Right arrow Plenary Papers
Right arrowRelated Letter in Blood Online
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

Blood, 1 February 2002, Vol. 99, No. 3, pp. 754-758

PLENARY PAPER

Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene

Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, and Hervé Watier

From Service d'Oncologie Médicale et Maladies du Sang et Laboratoire d'Immunologie, Centre Hospitalier Régional et Universitaire de Tours and UPRES-EA 3249 "Cellules hématopoïétiques, hémostase et greffe," Université de Tours; and Service d'Hématologie, Centre Hospitalier Lyon-Sud et Centre Jean Bernard, Le Mans, France.

Given that the Fcgamma RIIIa receptor 158V allotype displays a higher affinity for human immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this study was to determine the influence of that FCGR3A polymorphism on the therapeutic response to rituximab, an anti-CD20 humanized immunoglobulin G1 increasingly used in the treatment of non-Hodgkin lymphomas. The FCGR3A-158V/F genotype was determined in 49 patients having received rituximab for a previously untreated follicular non-Hodgkin lymphoma. The clinical response and the disappearance of the BCL2-JH gene rearrangement in both peripheral blood and bone marrow were evaluated at 2 months (M2) and at 1 year (M12). The study population consisted of 20% FCGR3A-158V homozygous patients, 35% FCGR3A-158F homozygous patients, and 45% heterozygous patients (FCGR3A-158F carriers). The objective response rates at M2 and M12 were 100% and 90%, respectively, in FCGR3A-158V homozygous patients compared with 67% (P = .03) and 51% (P = .03), respectively, in FCGR3A-158F carriers. A disappearance of the BCL2-JH gene rearrangement in both peripheral blood and marrow was observed at M12 in 5 of 6 of homozygous FCGR3A-158V patients compared with 5 of 17 of FCGR3A-158F carriers (P = .03). The homozygous FCGR3A-158V genotype was confirmed to be the single parameter associated with clinical and molecular responses by multivariate analysis. This study showed an association between the FCGR3A genotype and clinical and molecular responses to rituximab. This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas.

© 2002 by The American Society of Hematology.
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?

Related Letter in Blood Online:

Implication for how the single nucleotide polymorphism (SNP) of Fc receptor, Fcgamma RIIIa alters the interaction with anti-CD20 monoclonal antibody
Yasuo Oshima, Akio Fujimura, Guillaume Cartron, Laurent Dacheux, Gilles Salles, Philippe Solal-Celigny, Pierre Bardos, Philippe Colombat, and Hervé Watier
Blood 2002 99: 4649-4650. [Full Text] [PDF]



This article has been cited by other articles:


Home page
BloodHome page
V. Minard-Colin, Y. Xiu, J. C. Poe, M. Horikawa, C. M. Magro, Y. Hamaguchi, K. M. Haas, and T. F. Tedder
Lymphoma depletion during CD20 immunotherapy in mice is mediated by macrophage Fc{gamma}RI, Fc{gamma}RIII, and Fc{gamma}RIV
Blood, August 15, 2008; 112(4): 1205 - 1213.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Meyer zum Buschenfelde, Y. Feuerstacke, K. S. Gotze, K. Scholze, and C. Peschel
GM1 Expression of Non-Hodgkin's Lymphoma Determines Susceptibility to Rituximab Treatment
Cancer Res., July 1, 2008; 68(13): 5414 - 5422.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
P. V. Beum, M. A. Lindorfer, F. Beurskens, P. T. Stukenberg, H. M. Lokhorst, A. W. Pawluczkowycz, P. W. H. I. Parren, J. G. J. van de Winkel, and R. P. Taylor
Complement Activation on B Lymphocytes Opsonized with Rituximab or Ofatumumab Produces Substantial Changes in Membrane Structure Preceding Cell Lysis
J. Immunol., July 1, 2008; 181(1): 822 - 832.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
C. A. Walshe, S. A. Beers, R. R. French, C. H. T. Chan, P. W. Johnson, G. K. Packham, M. J. Glennie, and M. S. Cragg
Induction of Cytosolic Calcium Flux by CD20 Is Dependent upon B Cell Antigen Receptor Signaling
J. Biol. Chem., June 20, 2008; 283(25): 16971 - 16984.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
G. Cartron, L. Zhao-Yang, M. Baudard, T. Kanouni, V. Rouille, P. Quittet, B. Klein, and J.-F. Rossi
Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II Study
J. Clin. Oncol., June 1, 2008; 26(16): 2725 - 2731.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
H Marotte, G Paintaud, H Watier, and P Miossec
Rituximab-related late-onset neutropenia in a patient with severe rheumatoid arthritis
Ann Rheum Dis, June 1, 2008; 67(6): 893 - 894.
[Full Text] [PDF]


Home page
Cancer Res.Home page
A. Natsume, M. In, H. Takamura, T. Nakagawa, Y. Shimizu, K. Kitajima, M. Wakitani, S. Ohta, M. Satoh, K. Shitara, et al.
Engineered Antibodies of IgG1/IgG3 Mixed Isotype with Enhanced Cytotoxic Activities
Cancer Res., May 15, 2008; 68(10): 3863 - 3872.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al.
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer
J. Clin. Oncol., April 10, 2008; 26(11): 1789 - 1796.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Gianni
The "Other" Signaling of Trastuzumab: Antibodies Are Immunocompetent Drugs
J. Clin. Oncol., April 10, 2008; 26(11): 1778 - 1780.
[Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Xiu, C. P. Wong, J.-D. Bouaziz, Y. Hamaguchi, Y. Wang, S. M. Pop, R. M. Tisch, and T. F. Tedder
B Lymphocyte Depletion by CD20 Monoclonal Antibody Prevents Diabetes in Nonobese Diabetic Mice despite Isotype-Specific Differences in Fc{gamma}R Effector Functions
J. Immunol., March 1, 2008; 180(5): 2863 - 2875.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. S. Czuczman, S. Olejniczak, A. Gowda, A. Kotowski, A. Binder, H. Kaur, J. Knight, P. Starostik, J. Deans, and F. J. Hernandez-Ilizaliturri
Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels
Clin. Cancer Res., March 1, 2008; 14(5): 1561 - 1570.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Congy-Jolivet, A. Bolzec, D. Ternant, M. Ohresser, H. Watier, and G. Thibault
Fc{gamma}RIIIa Expression Is Not Increased on Natural Killer Cells Expressing the Fc{gamma}RIIIa-158V Allotype
Cancer Res., February 15, 2008; 68(4): 976 - 980.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
T. Tawara, K. Hasegawa, Y. Sugiura, K. Harada, T. Miura, S. Hayashi, T. Tahara, M. Ishikawa, H. Yoshida, K. Kubo, et al.
Complement Activation Plays a Key Role in Antibody-Induced Infusion Toxicity in Monkeys and Rats
J. Immunol., February 15, 2008; 180(4): 2294 - 2298.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
S.-Y. Wang, E. Racila, R. P. Taylor, and G. J. Weiner
NK-cell activation and antibody-dependent cellular cytotoxicity induced by rituximab-coated target cells is inhibited by the C3b component of complement
Blood, February 1, 2008; 111(3): 1456 - 1463.
[Abstract] [Full Text] [PDF]


Home page
Protein Eng Des SelHome page
G. Behar, S. Siberil, A. Groulet, P. Chames, M. Pugniere, C. Boix, C. Sautes-Fridman, J.-L. Teillaud, and D. Baty
Isolation and characterization of anti-Fc{gamma}RIII (CD16) llama single-domain antibodies that activate natural killer cells
Protein Eng. Des. Sel., January 1, 2008; 21(1): 1 - 10.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
S. Varchetta, N. Gibelli, B. Oliviero, E. Nardini, R. Gennari, G. Gatti, L. S. Silva, L. Villani, E. Tagliabue, S. Menard, et al.
Elements Related to Heterogeneity of Antibody-Dependent Cell Cytotoxicity in Patients Under Trastuzumab Therapy for Primary Operable Breast Cancer Overexpressing Her2
Cancer Res., December 15, 2007; 67(24): 11991 - 11999.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Oflazoglu, I. J. Stone, K. A. Gordon, I. S. Grewal, N. van Rooijen, C.-L. Law, and H.-P. Gerber
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
Blood, December 15, 2007; 110(13): 4370 - 4372.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
D. Daniel, B. Yang, D. A. Lawrence, K. Totpal, I. Balter, W. P. Lee, A. Gogineni, M. J. Cole, S. F. Yee, S. Ross, et al.
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts
Blood, December 1, 2007; 110(12): 4037 - 4046.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
M. L. Dustin, T. Starr, D. Coombs, G. R. Majeau, W. Meier, P. S. Hochman, A. Douglass, R. Vale, B. Goldstein, and A. Whitty
Quantification and Modeling of Tripartite CD2-, CD58FC Chimera (Alefacept)-, and CD16-mediated Cell Adhesion
J. Biol. Chem., November 30, 2007; 282(48): 34748 - 34757.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. C. Ryan, M. Hering, D. Peckham, C. F. McDonagh, L. Brown, K. M. Kim, D. L. Meyer, R. F. Zabinski, I. S. Grewal, and P. J. Carter
Antibody targeting of B-cell maturation antigen on malignant plasma cells
Mol. Cancer Ther., November 1, 2007; 6(11): 3009 - 3018.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
H. Yano, T. Ishida, A. Inagaki, T. Ishii, J. Ding, S. Kusumoto, H. Komatsu, S. Iida, H. Inagaki, and R. Ueda
Defucosylated Anti CC Chemokine Receptor 4 Monoclonal Antibody Combined with Immunomodulatory Cytokines: A Novel Immunotherapy for Aggressive/Refractory Mycosis Fungoides and Sezary Syndrome
Clin. Cancer Res., November 1, 2007; 13(21): 6494 - 6500.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
J. M. Roda, T. Joshi, J. P. Butchar, J. W. McAlees, A. Lehman, S. Tridandapani, and W. E. Carson III
The Activation of Natural Killer Cell Effector Functions by Cetuximab-Coated, Epidermal Growth Factor Receptor Positive Tumor Cells is Enhanced By Cytokines
Clin. Cancer Res., November 1, 2007; 13(21): 6419 - 6428.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
J. M. Roda and J. C. Byrd
Fc{gamma}RIIIa role in rituximab efficacy
Blood, October 1, 2007; 110(7): 2220 - 2220.
[Full Text] [PDF]


Home page
BloodHome page
X. Zhao, R. Lapalombella, T. Joshi, C. Cheney, A. Gowda, M. S. Hayden-Ledbetter, P. R. Baum, T. S. Lin, D. Jarjoura, A. Lehman, et al.
Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical
Blood, October 1, 2007; 110(7): 2569 - 2577.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
E. Hatjiharissi, L. Xu, D. D. Santos, Z. R. Hunter, B. T. Ciccarelli, S. Verselis, M. Modica, Y. Cao, R. J. Manning, X. Leleu, et al.
Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{gamma}RIIIa-158 V/V and V/F polymorphism
Blood, October 1, 2007; 110(7): 2561 - 2564.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
J. B. Stavenhagen, S. Gorlatov, N. Tuaillon, C. T. Rankin, H. Li, S. Burke, L. Huang, S. Johnson, E. Bonvini, and S. Koenig
Fc Optimization of Therapeutic Antibodies Enhances Their Ability to Kill Tumor Cells In vitro and Controls Tumor Expansion In vivo via Low-Affinity Activating Fc{gamma} Receptors
Cancer Res., September 15, 2007; 67(18): 8882 - 8890.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Li, M. E. Williams, J. B. Cousar, A. W. Pawluczkowycz, M. A. Lindorfer, and R. P. Taylor
Rituximab-CD20 Complexes Are Shaved from Z138 Mantle Cell Lymphoma Cells in Intravenous and Subcutaneous SCID Mouse Models
J. Immunol., September 15, 2007; 179(6): 4263 - 4271.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
Y. Tang, J. Lou, R. K. Alpaugh, M. K. Robinson, J. D. Marks, and L. M. Weiner
Regulation of Antibody-Dependent Cellular Cytotoxicity by IgG Intrinsic and Apparent Affinity for Target Antigen
J. Immunol., September 1, 2007; 179(5): 2815 - 2823.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
A. Ahuja, J. Shupe, R. Dunn, M. Kashgarian, M. R. Kehry, and M. J. Shlomchik
Depletion of B Cells in Murine Lupus: Efficacy and Resistance
J. Immunol., September 1, 2007; 179(5): 3351 - 3361.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Taylor, D. Hershman, N. Shah, N. Suciu-Foca, D. P. Petrylak, R. Taub, L. Vahdat, B. Cheng, M. Pegram, K. L. Knutson, et al.
Augmented HER-2 Specific Immunity during Treatment with Trastuzumab and Chemotherapy
Clin. Cancer Res., September 1, 2007; 13(17): 5133 - 5143.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. E. Strome, E. A. Sausville, and D. Mann
A Mechanistic Perspective of Monoclonal Antibodies in Cancer Therapy Beyond Target-Related Effects
Oncologist, September 1, 2007; 12(9): 1084 - 1095.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
W. Zhang, M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H.-M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al.
FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab
J. Clin. Oncol., August 20, 2007; 25(24): 3712 - 3718.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
E. Carlotti, G. A. Palumbo, E. Oldani, D. Tibullo, S. Salmoiraghi, A. Rossi, J. Golay, A. Pulsoni, R. Foa, and A. Rambaldi
Fc{gamma}RIIIA and Fc{gamma}RIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab
Haematologica, August 1, 2007; 92(8): 1127 - 1130.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. Morgensztern and R. Govindan
Is There a Role for Cetuximab in Non Small Cell Lung Cancer?
Clin. Cancer Res., August 1, 2007; 13(15): 4602s - 4605s.
[Abstract] [Full Text] [PDF]


Home page
haematolHome page
Z. Mitrovic, I. Aurer, I. Radman, R. Ajdukovic, J. Sertic, and B. Labar
FC{gamma}RIIIA and FC{gamma}RIIA polymorphisms are not associated with response to rituximab and CHOP in patients with diffuse large B-cell lymphoma
Haematologica, July 1, 2007; 92(7): 998 - 999.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
H. Horner, C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer
Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity
J. Immunol., July 1, 2007; 179(1): 337 - 345.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
M. Barok, J. Isola, Z. Palyi-Krekk, P. Nagy, I. Juhasz, G. Vereb, P. Kauraniemi, A. Kapanen, M. Tanner, G. Vereb, et al.
Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance
Mol. Cancer Ther., July 1, 2007; 6(7): 2065 - 2072.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. P. Treon, Z. R. Hunter, J. Matous, R. M. Joyce, B. Mannion, R. Advani, D. Cook, J. Songer, J. Hill, B. R. Kaden, et al.
Multicenter Clinical Trial of Bortezomib in Relapsed/Refractory Waldenstrom's Macroglobulinemia: Results of WMCTG Trial 03-248
Clin. Cancer Res., June 1, 2007; 13(11): 3320 - 3325.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
D. N. Forthal, P. B. Gilbert, G. Landucci, and T. Phan
Recombinant gp120 Vaccine-Induced Antibodies Inhibit Clinical Strains of HIV-1 in the Presence of Fc Receptor-Bearing Effector Cells and Correlate Inversely with HIV Infection Rate
J. Immunol., May 15, 2007; 178(10): 6596 - 6603.
[Abstract] [Full Text] [PDF]